Vanda Hid Off-Label Fraud Scheme From Investors, Suit Says
Disgruntled Vanda Pharmaceuticals Inc. shareholders filed a proposed securities class action against the company Monday that alleges Vanda executives misled investors for years by aggressively marketing drugs for nonapproved uses to...To view the full article, register now.
Already a subscriber? Click here to view full article